Boehringer Ingelheim and Alpha Pharma Collaborate to localize the production of one of its Type 2 Diabetes Medicines in Saudi Arabia
Boehringer Ingelheim is driving localization capacities with robust partnerships in alignment with Vision 2030
Search
A Clear Vision
Take a tour of our journey into Retinal Health through this interactive infographic or descriptive audio recording, and learn how we aim to preserve or restore vision in people with retinal diseases.
Vision & Values
Vision & Values
Our Vision
At Boehringer Ingelheim, we have expanded our global research and development activities to tackle eye diseases, specifically those affecting the back of the eye.
Research in Diabetic Macular Ischemia
There are no available treatments for DMI. Scientists at Boehringer Ingelheim are working hard to change this.
Stargardt Disease
Stargardt Disease is a hereditary condition causing and progressive vision loss, typically during childhood or adolescence.
A Deep Dive into Wet AMD
Wet AMD is a disease of the central portion of the retina (the macula) which is responsible for high visual acuity that allows for color vision, reading and facial recognition
Diabetic Retinopathy
Diabetic retinopathy affects 1 in 3 people with diabetes and is the leading cause of vision loss in adults of working age. It is a growing epidemic that is expected to increase as the incidence of diabetes escalates across the globe.
Geographic Atrophy
Geographic Atrophy is a slowly progressing, yet damaging form of AMD. Approximately 5 million people have Geographic Atrophy worldwide, with disease prevalence increasing with age. It is characterized by regions of cell death in the retina.
Patient Organizations
Boehringer Ingelheim’s core principles and vision guide our work with patient organisations.
Resizing our Carbon Footprint
The ecological balance of the world is at a tipping point.
Guardians for health
A global initiative to reduce mortality, cardiovascular and kidney complications in type 2 diabetes through adherence to clinical guidelines.
Obesity
Obesity
MORE GREEN: Environmental sustainability at a glance
On Earth Day, we share the progress of our global environmental sustainability MORE GREEN program and what the team is tackling, all 365 days of the year.
Retinal Health Research
Read about our holistic approach to retinal health research.
Complications of Diabetic Retinopathy
Both Diabetic Macular Edema and Ischemia are maculopathies, they specifically affect the macula, responsible for high visual acuity.
Boehringer Ingelheim inaugurates new milestone on its long-term commitment to the Kingdom
Boehringer Ingelheim inaugurates new milestone on its long-term commitment to the Kingdom
sustainably fighting rabies info hub
Did you know that every nine minutes, rabies takes a human life? Find out how we support the elimination of this deadly disease.
Circular economy
Boehringer Ingelheim strives to use resources for as long as possible, process them for reuse or recycle them.
Retinal health
We are looking for new early-science collaborations and invite you to join our expanding community of innovation partners in Retinal Health.
What Our Partners Say
What Our Partners Say
Behind the Lab
Delve behind the lab to see how our Retinal Health scientists are spearheading research into novel therapeutics to treat retinopathies.
About Us
About us
100-year anniversary of BI in respiratory care
100-year anniversary of Boehringer Ingelheim in respiratory care
Our Innovation Strategy
Our discovery research strategy is designed to sustain our track record of innovation and look for new and breakthrough medicines.